Answer
Omjjara (momelotinib) is contraindicated during breastfeeding because a risk to the breastfed child cannot be excluded, and whether momelotinib or its metabolites enter human milk is unknown.
Sources for this answer
- Omjjara 150 mg film-coated tabletsGlaxoSmithKline UK · emc · SmPC §4.6 Fertility, pregnancy and lactation · Version 4Document updated
Sources checked